Tíz év telt el azóta, hogy 2007-ben megjelent a Dry Eye WorkShop (DEWS) Report, mely összefoglalta a száraz szemről a szakirodalomban akkor elérhető legfontosabb információkat. Azóta közlemények százai jelentek meg ebben a témakörben, és eljött az idő az újabb összegzésre. A Tear Film & Ocular Surface Society (TFOS) szervezésében 12 munkacsoport összegezte a száraz szemmel kapcsolatos régi és új adatokat: megszületett a DEWS II Report. Ebben a közleményben a szerzők összefoglalják azokat a legfontosabb változásokat, amelyek a definíciótól a felosztáson és a diagnosztikán át a terápiáig a száraz szem vonatkozásában megváltoztak, és amelyekről a nem szemészként, más szakterületen dolgozó specialistáknak tájékozódni érdemes. A TFOS által közzétett DEWS II Report 11 alfejezetből áll. Teljesen új fejezetek szólnak az érzékelés/fájdalom szerepéről és a iatrogén száraz szemről. Orv Hetil. 2018; 159(20): 775–785.
TFOS DEWS II Report. Tear Film & Ocular Surface Work Shop II. Report. Ocul Surf. 2017; 15: 269–649.
Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. Contact Lens Assoc Ophthalmol J. 1995; 21: 221–232.
TFOS DEWS Report. 2007 Report of the International Dry Eye WorkShop (DEWS). Ocul Surf. 2007; 5: 65–204.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 75–92.
Bron AJ, de Pavia CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017; 15: 438–510.
Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009; 50: 3203–3209.
Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012; 31: 271–285.
Argueso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002; 43: 1004–1011.
Morrison M, Allen PZ. Lactoperoxidase: identification and isolation from Harderian and lacrimal glands. Science 1966; 152: 1626–1628.
Alexander JH, Young JA, van Lennep EW. The ultrastructure of the duct system in the rat extraorbital lacrimal gland. Z Zellforsch Mikrosk Anat. 1973; 144: 453–466.
Chung CW, Tigges M, Stone RA. Peptidergic innervation of the primate meibomian gland. Invest Ophthalmol Vis Sci. 1996; 37: 238–245.
Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004; 137: 337–342.
Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009; 147: 198–205.
Belmonte C, Acosta MC, Merayo-Lloves J, et al. What causes eye pain? Curr Ophthalmol Rep. 2015; 3: 111–121.
Sullivan B. Challenges in using signs and symptoms to evaluate new bio-markers of dry eye disease. Ocul Surf. 2014; 12: 2–9.
Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003; 136: 318–326.
Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009; 127: 763–768.
Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997; 124: 723–728.
Sullivan DA, Hann LE. Hormonal influence on the secretory immune system of the eye: endocrine impact on the lacrimal gland accumulation and secretion of IgA and IgG. J Steroid Biochem. 1989; 34: 253–262.
Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011; 52: 1994–2005.
Sullivan DA, Krenzer KL, Sullivan BD, et al. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999; 40: 1261–1265.
Thody AJ, Shuster S. Control and function of sebaceous glands. Physiol Rev. 1989; 69: 383–416.
Obata H, Yamamoto S, Horiuchi H, et al. Histopathologic study of human lacrimal gland. Statistical analysis with special reference to aging. Ophthalmology 1995; 102: 678–686.
Leach NE, Wallis NE, Lothringer LL, et al. Corneal hydration changes during the normal menstrual cycle – a preliminary study. J Reprod Med. 1971; 6: 201–204.
Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008; 8: 737–744.
Vachon G. Iatrogenic disease. In: Mullner RM (ed.) Encyclopedia of Health Services Research. SAGE Publications Inc., Thousand Oaks, CA, 2009; pp. 623–625.
Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. J Ophthalmol. 2012; 2012: 285851.
Franunfelder F, Fraunfelder FW, Chambers WA. Clinical ocular toxicology. Drugs, Chemicals and Herbs. Elsevier Saunders, Philadelphia, PA, 2008.
Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007; 17: 341–349.
Benito A, Pérez GM, Mirabet S, et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes. J Cataract Refrac Surg. 2011; 37: 1481–1487.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology Report. Ocul Surf. 2017; 15: 539–574.
Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 108–152.
Li M, Gong L, Chapin WJ, et al. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012; 53: 5722–5727.
Gumus K, Crockett CH, Rao K, et al. Noninvasive assessment of tear stability with the tear stability analysis system in tear dysfunction patients. Invest Ophthalmol Vis Sci. 2011; 52: 456–461.
Németh J, Erdélyi B, Csákány B, et al. High-speed videotopographic measurement of tear film build-up time. Invest Ophthalmol Vis Sci. 2002; 43: 1783–1790.
Potvin R, Makari S, Rapuano CJ. Tear film osmolarity and dry eye disease: a review of the literature. Clin Ophthalmol. 2015; 9: 2039–2047.
Szalai E, Berta A, Szekanecz Z, et al. Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system. Cornea 2012; 31: 867–871.
Bron AJ, Argüeso P, Irkec M, et al. Clinical staining of the ocular surface: mechanisms and interpretations. Prog Retin Eye Res. 2015; 44: 36–61.
Bandlitz S, Purslow C, Murphy PJ, et al. Comparison of a new portable digital meniscometer and optical coherence tomography in tear meniscus radius measurement. Acta Ophthalmol. 2014; 92: 112–118.
Knop E, Knop N, Millar T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011; 52: 1938–1978.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and therapy report. Ocul Surf. 2017; 15: 575–628.
Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt. 2009; 29: 573–583.
Ziakas NG, Boboridis KG, Terzidou C, et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Exp Ophthalmol. 2010; 38: 683–687.
Hamano T. Lacrimal duct occlusion in the treatment of dry eye. Semin Ophthalmol. 2005; 20: 71–74.
Qin J, Zhang L, Cai ZG, et al. Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. Br J Ophthalmol. 2013; 97: 1123–1128.
Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52: 2050–2064.
Geerling G, Borrelli M. Adnexal surgery for severe ocular surface disease. Semin Ophthalmol. 2005; 20: 101–112.
Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004; 138: 444–457.
Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016; 26: 287–296.
Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016; 14: 207–215.